MHLW To Consider Switch Of 19 Drugs to OTC, Including 12 Hypertension Products
This article was originally published in PharmAsia News
TOKYO - As a means to reduce national healthcare costs, Japan's Ministry of Health, Labor and Welfare June 7 released 19 pharmaceutical drugs for deliberation by its policy commission as potential switches to over-the-counter pharmaceuticals. The list included 12 hypertension drugs to be sold OTC, believed to be the first time in the world
You may also be interested in...
The First Subcommittee on New Drugs at Japan's Ministry of Health June 3 recommended six drugs for approval, including Wyeth/Pfizer's Viviant (bazedoxifene), clearing a hurdle for the merged companies' lead selective estrogen reuptake modulator for postmenopausal osteoporosis in Japan's crowded market
SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).